Myriad's Q2 Revenues Increase 21 Percent; New $200M Stock Buyback Program Launched
February 06, 2013
Myriad's Q2 Revenues Increase 21 Percent; New $200M Stock Buyback Program Launched
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Myriad Reports 20 Percent Q1 Revenue Growth, Rising Demand for Colorectal Cancer Test
November 2, 2011 / Pharmacogenomics Reporter - Continuing Push to Diversify Offerings, Myriad Licenses Chronix's Early Cancer Detection Technology
May 11, 2011 / Pharmacogenomics Reporter - Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
August 11, 2010 / Pharmacogenomics Reporter - Myriad Posts 21 Percent Revenue Growth for Q3
May 8, 2013 / GenomeWeb Daily News - Theranostics Health to Launch HER Signaling Assay, Marking Firm's First Commercial Test Release
May 3, 2013 / ProteoMonitor